From 17f98daa43108821fa2aff8a90019eced2bb6c49 Mon Sep 17 00:00:00 2001 From: Teleo Agents Date: Sun, 15 Mar 2026 19:28:17 +0000 Subject: [PATCH] extract: 2025-05-01-nejm-semaglutide-mash-phase3-liver Pentagon-Agent: Ganymede --- ...t cost impact inflationary through 2035.md | 6 +++++ ...-cardiovascular-and-metabolic-endpoints.md | 6 +++++ ...01-nejm-semaglutide-mash-phase3-liver.json | 24 +++++++++++++++++++ ...5-01-nejm-semaglutide-mash-phase3-liver.md | 13 +++++++++- 4 files changed, 48 insertions(+), 1 deletion(-) create mode 100644 inbox/archive/.extraction-debug/2025-05-01-nejm-semaglutide-mash-phase3-liver.json diff --git a/domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md b/domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md index 787d6d273..b004c7429 100644 --- a/domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md +++ b/domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md @@ -29,6 +29,12 @@ Real-world persistence data from 125,474 commercially insured patients shows the The Cell Press review characterizes GLP-1s as marking a 'system-level redefinition' of cardiometabolic management with 'ripple effects across healthcare costs, insurance models, food systems, long-term population health.' Obesity costs the US $400B+ annually, providing context for the scale of potential cost impact. The WHO issued conditional recommendations within 2 years of widespread adoption (December 2025), unusually fast for a major therapeutic category. + +### Additional Evidence (extend) +*Source: [[2025-05-01-nejm-semaglutide-mash-phase3-liver]] | Added: 2026-03-15* + +MASH indication adds a third organ-protection pathway (liver, after cardiovascular and kidney), strengthening the multi-indication economic case. However, the Value in Health Medicare study showed only $28M MASH savings—surprisingly small given the 63% clinical resolution rate, likely because MASH progression to transplant takes decades, placing most savings beyond the 10-year budget window. + --- Relevant Notes: diff --git a/domains/health/glp-1-multi-organ-protection-creates-compounding-value-across-kidney-cardiovascular-and-metabolic-endpoints.md b/domains/health/glp-1-multi-organ-protection-creates-compounding-value-across-kidney-cardiovascular-and-metabolic-endpoints.md index 1222d36b5..acf6c8138 100644 --- a/domains/health/glp-1-multi-organ-protection-creates-compounding-value-across-kidney-cardiovascular-and-metabolic-endpoints.md +++ b/domains/health/glp-1-multi-organ-protection-creates-compounding-value-across-kidney-cardiovascular-and-metabolic-endpoints.md @@ -30,6 +30,12 @@ For value-based care models and capitated payers, this multi-organ protection cr - Nature Medicine: additive benefits with SGLT2 inhibitors - First GLP-1 to receive FDA indication for CKD in T2D patients + +### Additional Evidence (extend) +*Source: [[2025-05-01-nejm-semaglutide-mash-phase3-liver]] | Added: 2026-03-15* + +NEJM Phase 3 trial adds liver protection as a third major organ system. Semaglutide achieved 62.9% MASH resolution vs 34.3% placebo, with meta-analysis showing reduced risk of major CV events, clinically significant portal hypertension, and all-cause mortality in MASLD/MASH patients. Some hepatoprotective effects operate independently of weight loss, suggesting direct GLP-1 receptor-mediated liver benefits. + --- Relevant Notes: diff --git a/inbox/archive/.extraction-debug/2025-05-01-nejm-semaglutide-mash-phase3-liver.json b/inbox/archive/.extraction-debug/2025-05-01-nejm-semaglutide-mash-phase3-liver.json new file mode 100644 index 000000000..2d7d51aad --- /dev/null +++ b/inbox/archive/.extraction-debug/2025-05-01-nejm-semaglutide-mash-phase3-liver.json @@ -0,0 +1,24 @@ +{ + "rejected_claims": [ + { + "filename": "glp-1-agonists-resolve-steatohepatitis-in-63-percent-of-mash-patients-through-mechanisms-partially-independent-of-weight-loss.md", + "issues": [ + "missing_attribution_extractor" + ] + } + ], + "validation_stats": { + "total": 1, + "kept": 0, + "fixed": 1, + "rejected": 1, + "fixes_applied": [ + "glp-1-agonists-resolve-steatohepatitis-in-63-percent-of-mash-patients-through-mechanisms-partially-independent-of-weight-loss.md:set_created:2026-03-15" + ], + "rejections": [ + "glp-1-agonists-resolve-steatohepatitis-in-63-percent-of-mash-patients-through-mechanisms-partially-independent-of-weight-loss.md:missing_attribution_extractor" + ] + }, + "model": "anthropic/claude-sonnet-4.5", + "date": "2026-03-15" +} \ No newline at end of file diff --git a/inbox/archive/2025-05-01-nejm-semaglutide-mash-phase3-liver.md b/inbox/archive/2025-05-01-nejm-semaglutide-mash-phase3-liver.md index 105ae4402..233ba561b 100644 --- a/inbox/archive/2025-05-01-nejm-semaglutide-mash-phase3-liver.md +++ b/inbox/archive/2025-05-01-nejm-semaglutide-mash-phase3-liver.md @@ -7,9 +7,13 @@ date: 2025-05-01 domain: health secondary_domains: [] format: paper -status: unprocessed +status: enrichment priority: medium tags: [glp-1, semaglutide, MASH, NASH, liver-disease, organ-protection] +processed_by: vida +processed_date: 2026-03-15 +enrichments_applied: ["glp-1-multi-organ-protection-creates-compounding-value-across-kidney-cardiovascular-and-metabolic-endpoints.md", "GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md"] +extraction_model: "anthropic/claude-sonnet-4.5" --- ## Content @@ -39,3 +43,10 @@ Phase 3 trial of semaglutide 2.4mg in patients with MASH and moderate or advance PRIMARY CONNECTION: [[GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035]] WHY ARCHIVED: Third organ-protection pathway (after CV and kidney) strengthens the case that GLP-1s should be evaluated as multi-organ protective agents, not just weight loss drugs EXTRACTION HINT: The multi-organ protection thesis may justify reframing the existing GLP-1 claim from a weight-loss-economics frame to a metabolic-disease-prevention frame + + +## Key Facts +- Resmetirom (Rezdiffra) was approved for MASH in March 2024 +- MASH is projected to become the leading cause of liver transplantation +- GLP-1 RAs reduce liver fat deposition, improve hepatocellular ballooning, and reduce lobular inflammation per 2025 meta-analysis +- Meta-analysis shows GLP-1 RAs associated with reduced risk of major CV events, clinically significant portal hypertension, and all-cause mortality in MASLD/MASH patients -- 2.45.2